Schistosoma mansoni infection causes oxidative stress and alters receptor for advanced glycation endproduct (RAGE) and tau levels in multiple organs in mice

International Journal for Parasitology

Volumn 43, Issue 5, 2013, Pages 371-379

  De Oliveira, Ramatis Birnfeld ^a   Senger, Mario Roberto ^b   Vasques, Laura Milan ^a   Gasparotto, Juciano ^a   Dos Santos, João Paulo Almeida ^a   De Bittencourt Pasquali, Matheus Augusto ^a   Moreira, José Claudio Fonseca ^a   Silva, Floriano Paes ^b   Gelain, Daniel Pens ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Antioxidant enzymes; Oxidative stress; RAGE; Schistosoma; Tau

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARBONYL DERIVATIVE; CATALASE; MANGANESE SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE; TAU PROTEIN;

ANTIOXIDANT; BRAIN; ENZYME; HOMEOSTASIS; PATHOLOGY; PROTEIN; REDOX CONDITIONS; RODENT; SCHISTOSOMIASIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; ENZYME ACTIVITY; HEART; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; SCHISTOSOMIASIS MANSONI; SPLEEN; TISSUE SPECIFICITY;

ANIMALS; CATALASE; CEREBRAL CORTEX; GENE EXPRESSION REGULATION; LUNG; MICE; MYOCARDIUM; OXIDATION-REDUCTION; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SUPEROXIDE DISMUTASE; TAU PROTEINS;

MUS; SCHISTOSOMA; SCHISTOSOMA MANSONI; TREMATODA;

EID: 84875250108     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2012.12.006     Document Type: Article

References (48)

1. Abdallahi O.M., Hanna S., De Reggi M., Gharib B. Visualization of oxygen radical production in mouse liver in response to infection with Schistosoma mansoni. Liver 1999, 19:495-500.
2. Aebi H. Catalase in vitro. Methods Enzymol. 1984, 105:121-126.
3. Agholme L., Lindstrom T., Kagedal K., Marcusson J., Hallbeck M. An in vitro model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical characteristics of mature neurons. J. Alzheimers Dis. 2010, 20:1069-1082.
4. Andrade Z.A. Schistosomal hepatopathy. Mem. Inst. Oswaldo Cruz 2004, 99:51-57.
5. Bartling B., Hofmann H.S., Weigle B., Silber R.E., Simm A. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 2005, 26:293-301.
6. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000, 26(Suppl. 1):S64-74.
7. Buckley S.T., Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J. Biomed. Biotechnol. 2010, 2010:917108.
8. Carod-Artal F.J. Neuroschistosomiasis. Expert Rev. Anti Infect. Ther. 2010, 8:1307-1318.
9. Carvalho V.T., Barbosa M.M., Nunes M.C., Cardoso Y.S., de Sa Filho I.M., Oliveira F.R., Antunes C.M., Lambertucci J.R. Early right cardiac dysfunction in patients with schistosomiasis mansoni. Echocardiography 2011, 28:261-267.
10. Coughlan M.T., Cooper M.E., Forbes J.M. Renal microvascular injury in diabetes: RAGE and redox signaling. Antioxid. Redox Signal. 2007, 9:331-342.
11. Coughlan M.T., Thorburn D.R., Penfold S.A., Laskowski A., Harcourt B.E., Sourris K.C., Tan A.L., Fukami K., Thallas-Bonke V., Nawroth P.P., Brownlee M., Bierhaus A., Cooper M.E., Forbes J.M. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J. Am. Soc. Nephrol. 2009, 20:742-752.
12. Creagh-Brown B.C., Quinlan G.J., Evans T.W. RAGE inhibition: healthy or harmful?. Crit. Care Med. 2010, 38:1487-1490.
13. Creagh-Brown B.C., Quinlan G.J., Evans T.W., Burke-Gaffney A. The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target?. Intensive Care Med. 2010, 36:1644-1656.
14. de Jesus A.R., Silva A., Santana L.B., Magalhaes A., de Jesus A.A., de Almeida R.P., Rego M.A., Burattini M.N., Pearce E.J., Carvalho E.M. Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J. Infect. Dis. 2002, 185:98-105.
15. de Water R., Van Marck E.A., Fransen J.A., Deelder A.M. Schistosoma mansoni: ultrastructural localization of the circulating anodic antigen and the circulating cathodic antigen in the mouse kidney glomerulus. Am. J. Trop. Med. Hyg. 1988, 38:118-124.
16. Dresch M.T., Rossato S.B., Kappel V.D., Biegelmeyer R., Hoff M.L., Mayorga P., Zuanazzi J.A., Henriques A.T., Moreira J.C. Optimization and validation of an alternative method to evaluate total reactive antioxidant potential. Anal. Biochem. 2009, 385:107-114.
17. El-Dosoky I., Van Marck E.A., Deelder A.M. Presence of Schistosoma mansoni antigens in liver, spleen and kidney of infected mice: a sequential study. Z. Parasitenkd. 1984, 70:491-497.
18. El-Sokkary G.H., Omar H.M., Hassanein A.F., Cuzzocrea S., Reiter R.J. Melatonin reduces oxidative damage and increases survival of mice infected with Schistosoma mansoni. Free Radic. Biol. Med. 2002, 32:319-332.
19. Elsammak M.Y., Al-Sharkaweey R.M., Ragab M.S., Amin G.A., Kandil M.H. IL-4 and reactive oxygen species are elevated in Egyptian patients affected with schistosomal liver disease. Parasite Immunol. 2008, 30:603-609.
20. Facundo H.T., Brandt C.T., Owen J.S., Lima V.L. Elevated levels of erythrocyte-conjugated dienes indicate increased lipid peroxidation in schistosomiasis mansoni patients. Braz. J. Med. Biol. Res. 2004, 37:957-962.
21. Fairfax K., Nascimento M., Huang S.C., Everts B., Pearce E.J. Th2 responses in schistosomiasis. Semin. Immunopathol. 2012, 34:863-871.
22. Franklin W.A. RAGE in lung tumors. Am. J. Respir. Crit. Care Med. 2007, 175:106-107.
23. Gharib B., Abdallahi O.M., Dessein H., De Reggi M. Development of eosinophil peroxidase activity and concomitant alteration of the antioxidant defenses in the liver of mice infected with Schistosoma mansoni. J. Hepatol. 1999, 30:594-602.
24. Goedert M., Jakes R., Crowther R.A., Hasegawa M., Smith M.J., Spillantini M.G. Intraneuronal filamentous tau protein and alpha-synuclein deposits in neurodegenerative diseases. Biochem. Soc. Trans. 1998, 26:463-471.
25. Gryseels B. Schistosomiasis. Infect. Dis. Clin. North Am. 2012, 26:383-397.
26. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 2007, Oxford University Press, Oxford. fourth ed.
27. Kolosionek E., Crosby A., Harhay M.O., Morrell N., Butrous G. Pulmonary vascular disease associated with schistosomiasis. Expert Rev. Anti Infect. Ther. 2010, 8:1467-1473.
28. Kouriba B., Traore H.A., Dabo A., Sangare L., Guindo H., Keita A.S., Reimert C.M., van Dam G.J., Deelder A.M., Doumbo O., Dessein A.J. Urinary disease in 2 Dogon populations with different exposure to Schistosoma haematobium infection: progression of bladder and kidney diseases in children and adults. J. Infect. Dis. 2005, 192:2152-2159.
29. Krstic D., Madhusudan A., Doehner J., Vogel P., Notter T., Imhof C., Manalastas A., Hilfiker M., Pfister S., Schwerdel C., Riether C., Meyer U., Knuesel I. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J. Neuroinflamm. 2012, 9:151.
30. La Flamme A.C., Patton E.A., Bauman B., Pearce E.J. IL-4 plays a crucial role in regulating oxidative damage in the liver during schistosomiasis. J. Immunol. 2001, 166:1903-1911.
31. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W., Shaltiel S., Stadtman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990, 186:464-478.
32. Li X.H., Lv B.L., Xie J.Z., Liu J., Zhou X.W., Wang J.Z. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol. Aging 2011, 33:1400-1410.
33. Misra H.P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972, 247:3170-3175.
34. Pasquali M.A., Gelain D.P., de Oliveira M.R., Behr G.A., da Motta L.L., da Rocha R.F., Klamt F., Moreira J.C. Vitamin A supplementation for different periods alters oxidative parameters in lungs of rats. J. Med. Food 2009, 12:1375-1380.
35. Pearce E.J. Priming of the immune response by schistosome eggs. Parasite Immunol. 2005, 27:265-270.
36. Pyrrho A.S., Lenzi H.L., Ramos J.A., Moura-Neto R., Cachem F.C., Santos da Silva C., Takiya C.M., Gattass C.R. Dexamethasone treatment improves morphological and hematological parameters in chronic experimental schistosomiasis. Parasitol. Res. 2004, 92:478-483.
37. Queisser M.A., Kouri F.M., Konigshoff M., Wygrecka M., Schubert U., Eickelberg O., Preissner K.T. Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am. J. Respir. Cell Mol. Biol. 2008, 39:337-345.
38. Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop. 2003, 86:161-183.
39. Roe A.D., Staup M.A., Serrats J., Sawchenko P.E., Rissman R.A. Lipopolysaccharide-induced tau phosphorylation and kinase activity-modulation, but not mediation, by corticotropin-releasing factor receptors. Eur. J. Neurosci. 2011, 34:448-456.
40. Ross A.G., McManus D.P., Farrar J., Hunstman R.J., Gray D.J., Li Y.S. Neuroschistosomiasis. J. Neurol. 2012, 259:22-32.
41. Salvemini D., Wang Z.Q., Wyatt P.S., Bourdon D.M., Marino M.H., Manning P.T., Currie M.G. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br. J. Pharmacol. 1996, 118:829-838.
42. Steinmann P., Keiser J., Bos R., Tanner M., Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis. 2006, 6:411-425.
43. Utzinger J., Chollet J., You J., Mei J., Tanner M., Xiao S. Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals. Acta Trop. 2001, 80:9-18.
44. Valente T., Gella A., Fernandez-Busquets X., Unzeta M., Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol. Dis. 2010, 37:67-76.
45. Wang J.Z., Xia Y.Y., Grundke-Iqbal I., Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheimers Dis. 2012, 33:S123-S139.
46. Wilson S., Vennervald B.J., Dunne D.W. Chronic hepatosplenomegaly in African school children: a common but neglected morbidity associated with schistosomiasis and malaria. PLoS Negl. Trop. Dis. 2011, 5:e1149.
47. Wynn T.A., Thompson R.W., Cheever A.W., Mentink-Kane M.M. Immunopathogenesis of schistosomiasis. Immunol. Rev. 2004, 201:156-167.
48. Yoshiyama Y., Kojima A., Ishikawa C., Arai K. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J. Alzheimers Dis. 2010, 22:295-306.